iShares Biotechnology ETF
520 hedge funds and large institutions have $5.06B invested in iShares Biotechnology ETF in 2017 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 179 increasing their positions, 186 reducing their positions, and 76 closing their positions.
22% more capital invested
Capital invested by funds: $4.15B → $5.06B (+$910M)
16.59% more ownership
Funds ownership: 161.41% → 177.99% (+17%)
0% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 76
0% less funds holding
Funds holding: 522 → 520 (-2)
4% less repeat investments, than reductions
Existing positions increased: 179 | Existing positions reduced: 186
5% less funds holding in top 10
Funds holding in top 10: 21 → 20 (-1)
35% less call options, than puts
Call options by funds: $496M | Put options by funds: $763M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$187M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$157M |
| 3 |
Morgan Stanley
New York
|
+$71.5M |
| 4 |
JP Morgan Chase
New York
|
+$70.5M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$67.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Natixis
Paris,
France
|
-$39.9M |
| 2 |
RIG
RiverFront Investment Group
Richmond,
Virginia
|
-$35.6M |
| 3 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$30.9M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$30.1M |
| 5 |
Jane Street
New York
|
-$29.9M |
IBB Hedge Fund Activity: Q1 2017 in Review
520 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2017, worth a combined $5.06B — up 22% from $4.15B a quarter earlier.
Fund positioning in IBB was balanced in Q1 2017: 76 funds opened new positions, 76 closed out, 179 added to existing stakes and 186 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $187M. The largest seller was Natixis, exiting entirely with an estimated $39.9M sold.
- 520 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2017, down from 522 in Q4 2016.
- Funds reported $5.06B of iShares Biotechnology ETF stock for Q1 2017, up 22% quarter-over-quarter.
- 76 funds opened new iShares Biotechnology ETF positions in Q1 2017 and 76 closed out, a net change of 0 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2017 was Goldman Sachs, an estimated $187M added.
- The largest iShares Biotechnology ETF seller in Q1 2017 was Natixis, an estimated $39.9M sold.
Based on aggregated 13F filings for Q1 2017.